Posters/Publications

poster

The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model

AASLD

Date - 11/2018

poster

Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone

Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

Date - 11/2018

poster

Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN

Keystone Symposium on Organ Crosstalk in Obesity and NAFLD

Date - 01/2018

poster

Fatty acid synthase inhibitor TVB-3664 reverses multiple components of diet-induced nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone and reduces collagen accumulation in bleomycin-induced murine skin fibrosis

AASLD

Date - 10/2017

poster

Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans.

AASLD

Date - 10/2017

oral

First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640

AACR Annual Meeting

Date - 04/2017

poster

Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH

EASL International Liver Congress

Date - 04/2017

paper

Fatty Acid Synthase – Modern Tumor Cell Biology Insights into a Classical Oncology Target

Pharmacology and Therapeutics

Date - 02/2017

poster

Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel

San Antonio Breast Cancer Symposium

Date - 12/2016

paper

FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression

EBioMedicine

Date - 12/2016

Posters/Publications

The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model

Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone

Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN

Fatty acid synthase inhibitor TVB-3664 reverses multiple components of diet-induced nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone and reduces collagen accumulation in bleomycin-induced murine skin fibrosis

Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans.

First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640

Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH

Fatty Acid Synthase – Modern Tumor Cell Biology Insights into a Classical Oncology Target

Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel

FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression

Site map

Contact us